Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy

Giovanni Schifitto, Constantin Yiannoutsos, D. M. Simpson, B. T. Adornato, E. J. Singer, H. Hollander, C. M. Marra, M. Rubin, B. A. Cohen, T. Tucker, I. J. Koralnik, D. Katzenstein, B. Haidich, M. E. Smith, S. Shriver, L. Millar, D. B. Clifford, J. C. McArthur

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.

Original languageEnglish (US)
Pages (from-to)1313-1316
Number of pages4
JournalNeurology
Volume57
Issue number7
StatePublished - Oct 9 2001
Externally publishedYes

Fingerprint

Polyneuropathies
Nerve Growth Factor
HIV
Nerve Growth Factors
Neurologic Examination
Nerve Fibers
Double-Blind Method
Acquired Immunodeficiency Syndrome
Pain
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Schifitto, G., Yiannoutsos, C., Simpson, D. M., Adornato, B. T., Singer, E. J., Hollander, H., ... McArthur, J. C. (2001). Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology, 57(7), 1313-1316.

Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. / Schifitto, Giovanni; Yiannoutsos, Constantin; Simpson, D. M.; Adornato, B. T.; Singer, E. J.; Hollander, H.; Marra, C. M.; Rubin, M.; Cohen, B. A.; Tucker, T.; Koralnik, I. J.; Katzenstein, D.; Haidich, B.; Smith, M. E.; Shriver, S.; Millar, L.; Clifford, D. B.; McArthur, J. C.

In: Neurology, Vol. 57, No. 7, 09.10.2001, p. 1313-1316.

Research output: Contribution to journalArticle

Schifitto, G, Yiannoutsos, C, Simpson, DM, Adornato, BT, Singer, EJ, Hollander, H, Marra, CM, Rubin, M, Cohen, BA, Tucker, T, Koralnik, IJ, Katzenstein, D, Haidich, B, Smith, ME, Shriver, S, Millar, L, Clifford, DB & McArthur, JC 2001, 'Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy', Neurology, vol. 57, no. 7, pp. 1313-1316.
Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology. 2001 Oct 9;57(7):1313-1316.
Schifitto, Giovanni ; Yiannoutsos, Constantin ; Simpson, D. M. ; Adornato, B. T. ; Singer, E. J. ; Hollander, H. ; Marra, C. M. ; Rubin, M. ; Cohen, B. A. ; Tucker, T. ; Koralnik, I. J. ; Katzenstein, D. ; Haidich, B. ; Smith, M. E. ; Shriver, S. ; Millar, L. ; Clifford, D. B. ; McArthur, J. C. / Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. In: Neurology. 2001 ; Vol. 57, No. 7. pp. 1313-1316.
@article{f1c28461de5245ddb6ee21bae46538d0,
title = "Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy",
abstract = "HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.",
author = "Giovanni Schifitto and Constantin Yiannoutsos and Simpson, {D. M.} and Adornato, {B. T.} and Singer, {E. J.} and H. Hollander and Marra, {C. M.} and M. Rubin and Cohen, {B. A.} and T. Tucker and Koralnik, {I. J.} and D. Katzenstein and B. Haidich and Smith, {M. E.} and S. Shriver and L. Millar and Clifford, {D. B.} and McArthur, {J. C.}",
year = "2001",
month = "10",
day = "9",
language = "English (US)",
volume = "57",
pages = "1313--1316",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy

AU - Schifitto, Giovanni

AU - Yiannoutsos, Constantin

AU - Simpson, D. M.

AU - Adornato, B. T.

AU - Singer, E. J.

AU - Hollander, H.

AU - Marra, C. M.

AU - Rubin, M.

AU - Cohen, B. A.

AU - Tucker, T.

AU - Koralnik, I. J.

AU - Katzenstein, D.

AU - Haidich, B.

AU - Smith, M. E.

AU - Shriver, S.

AU - Millar, L.

AU - Clifford, D. B.

AU - McArthur, J. C.

PY - 2001/10/9

Y1 - 2001/10/9

N2 - HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.

AB - HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.

UR - http://www.scopus.com/inward/record.url?scp=0035833962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035833962&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 1313

EP - 1316

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -